A research team from the Medical University of Vienna and the Medical University of Graz has discovered a previously unknown genetic cause of hereditary optic atrophy, a degenerative disease of the ...

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression ...

Please provide your email address to receive an email when new articles are posted on . Band optic atrophy is described as a horizontal band of optic disc pallor, often associated with a contralateral ...

A research team from the Medical University of Vienna and the Medical University of Graz has discovered a previously unknown genetic cause of hereditary optic atrophy, a degenerative disease of the ...

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression ...

A research team has successfully demonstrated the world's first gene-editing treatment for Leber's hereditary optic neuropathy (LHON). The study was conducted in collaboration with the Seoul National ...

A novel treatment for Leber's Hereditary Optic Neuropathy (LHON), a rare genetic disease that can lead to sudden loss of vision, has been approved for NHS patients following a successful clinical ...

Stoke Therapeutics (NASDAQ:STOK) has enrolled first patient in a prospective natural history study of people ages 8 to 60 who are living with autosomal dominant optic atrophy (ADOA). FALCON is a ...

Autosomal dominant optic atrophy (ADOA) is a rare genetic disease that causes progressive and irreversible vision loss in both eyes starting in the first decade of life. There is currently no ...

Autosomal dominant optic atrophy (ADOA), the most common genetic optic neuropathy, is an insidious disease. It often presents slowly during childhood by way of blurry vision, trouble reading or ...